Mereo BioPharma Group plc Investors with Losses in Excess of $100K Encouraged to Secure Counsel Before Important Deadline in Securities Class Action.

Mereo BioPharma Group plc investors with losses over $100K are encouraged to secure counsel before the April 6, 2026, deadline in a securities class action lawsuit. The lawsuit alleges that defendants provided investors with material information regarding the expected results of Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta, but failed to disclose the true nature of the studies. If you purchased Mereo ADSs during the Class Period, you may be entitled to compensation through a contingency fee arrangement.